Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Top Cited Papers
- 20 July 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 21 (8), 922-926
- https://doi.org/10.1038/nm.3884
Abstract
Clinical testing of BCR inhibition on DLBCL reveals determinants of response. The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like (ABC) and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling1. The ABC subtype has a ∼40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies2. We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling. In a phase 1/2 clinical trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106). ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), especially those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways. However, the highest number of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms. These results support the selective development of ibrutinib for the treatment of ABC DLBCL.Keywords
This publication has 18 references indexed in Scilit:
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomicsNature, 2012
- Pathogenesis of Human B Cell LymphomasAnnual Review of Immunology, 2012
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2011
- Oncogenically active MYD88 mutations in human lymphomaNature, 2010
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell LymphomaScience, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Peptide-mediated Interference of TIR Domain Dimerization in MyD88 Inhibits Interleukin-1-dependent Activation of NF-κBPublished by Elsevier BV ,2005
- Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma CellsThe Journal of Experimental Medicine, 2001